These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases. Zhu L; Zhu H Virol Sin; 2014 Dec; 29(6):327-42. PubMed ID: 25547680 [TBL] [Abstract][Full Text] [Related]
23. Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes. Kashanchi F; Kehn-Hall K Curr Pharm Des; 2009; 15(21):2520-32. PubMed ID: 19601848 [TBL] [Abstract][Full Text] [Related]
24. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. Reusser P J Hosp Infect; 1996 Aug; 33(4):235-48. PubMed ID: 8864937 [TBL] [Abstract][Full Text] [Related]
25. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Gilbert C; Bestman-Smith J; Boivin G Drug Resist Updat; 2002 Apr; 5(2):88-114. PubMed ID: 12135584 [TBL] [Abstract][Full Text] [Related]
26. The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside. Liu X; Cohen JI Virology; 2015 May; 479-480():568-77. PubMed ID: 25798530 [TBL] [Abstract][Full Text] [Related]
27. A short commentary on the review by Weller and Kuchta: the DNA helicase-primase complex as a target for herpes virus infection. Field HJ Expert Opin Ther Targets; 2013 Oct; 17(10):1113-4. PubMed ID: 24044544 [No Abstract] [Full Text] [Related]
28. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Michel D; Mertens T Biochim Biophys Acta; 2004 Mar; 1697(1-2):169-80. PubMed ID: 15023359 [TBL] [Abstract][Full Text] [Related]
29. Management of herpesvirus infections. Evans CM; Kudesia G; McKendrick M Int J Antimicrob Agents; 2013 Aug; 42(2):119-28. PubMed ID: 23820015 [TBL] [Abstract][Full Text] [Related]
30. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Coen DM; Schaffer PA Nat Rev Drug Discov; 2003 Apr; 2(4):278-88. PubMed ID: 12669027 [TBL] [Abstract][Full Text] [Related]
31. Current and potential therapies for the treatment of herpesvirus infections. Villarreal EC Prog Drug Res; 2001; 56():77-120. PubMed ID: 11417115 [TBL] [Abstract][Full Text] [Related]
32. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Field AK; Biron KK Clin Microbiol Rev; 1994 Jan; 7(1):1-13. PubMed ID: 8118786 [TBL] [Abstract][Full Text] [Related]
33. Biochemical aspects of the selective antiherpes activity of nucleoside analogues. De Clercq E Biochem Pharmacol; 1984 Jul; 33(14):2159-69. PubMed ID: 6147138 [No Abstract] [Full Text] [Related]
34. Non-nucleoside inhibitors of herpesviruses. Wathen MW Rev Med Virol; 2002; 12(3):167-78. PubMed ID: 11987142 [TBL] [Abstract][Full Text] [Related]
35. KSHV targeted therapy: an update on inhibitors of viral lytic replication. Coen N; Duraffour S; Snoeck R; Andrei G Viruses; 2014 Nov; 6(11):4731-59. PubMed ID: 25421895 [TBL] [Abstract][Full Text] [Related]
38. Antiviral Therapies for Herpesviruses: Current Agents and New Directions. Poole CL; James SH Clin Ther; 2018 Aug; 40(8):1282-1298. PubMed ID: 30104016 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. Prichard MN; Hartline CB; Harden EA; Daily SL; Beadle JR; Valiaeva N; Kern ER; Hostetler KY Antimicrob Agents Chemother; 2008 Dec; 52(12):4326-30. PubMed ID: 18852272 [TBL] [Abstract][Full Text] [Related]